. 2017 Mar 16;7:44668. doi: 10.1038/srep44668

Table 2. Comparison of the statistical results of the preclinical validations of the 3-plex immunoassays based on the QDEM and Luminex xMAP^® technologies for the diagnosis of lung cancer.

Immunoassay	Marker	Univariate analysis		Multivariate analysis
Immunoassay	Marker	P value	AUC	Model AUC	Model P value
QDEM	AMBP	<0.05	0.899	0.992	<0.05
	PRDX2	<0.05	0.747
	PARK7	<0.05	0.192
xMAP^®	AMBP	<0.05	0.947	0.989	<0.05
	PRDX2	<0.05	0.709
	PARK7	<0.05	0.152

AMBP, α-1-microglobulin/bikunin precursor; AUC, area under the curve; LoQ, limit of quantification; PRDX2, peroxiredoxin 2; PARK7, Parkinson disease protein 7; QDEM, quantum dot encoded microspheres.

Table 2. Comparison of the statistical results of the preclinical validations of the 3-plex immunoassays based on the QDEM and Luminex xMAP® technologies for the diagnosis of lung cancer.

Table 2. Comparison of the statistical results of the preclinical validations of the 3-plex immunoassays based on the QDEM and Luminex xMAP^® technologies for the diagnosis of lung cancer.